



m4067n

PURGEDFood and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

August 14, 2000

WARNING LETTER**CERTIFIED MAIL**
RETURN RECEIPT REQUESTED

Refer to MIN 00 - 47

Richard Devoll
Managing Director for Serologicals
Seramed, Inc.
780 Park North Boulevard, Suite 110
Clarkston, Georgia 30021

Dear Mr. Devoll:

The Food and Drug Administration (FDA) conducted an inspection of your facility, Seramed, Inc., located at 2111 West North Avenue, Milwaukee, WI, from July 11 - 18, 2000. During the inspection FDA investigators documented violations of Section 501(a)(2)(B) of the Federal Food, Drug and Cosmetic Act (FD&C Act) and deviations from the applicable standards and requirements of Subchapter F Parts 600 - 680, Title 21, Code of Federal Regulations (21 CFR 600-680). The deviations noted on the form FDA-483, Inspectional Observations, issued at the conclusion of the inspection include, but are not limited to, the following:

1. Collection of plasma from a donor who donated not less than two days apart and more frequently than twice in a 7-day period [21 CFR 640.65(b)(8)].
2. Failure to establish adequate procedures to evaluate donor suitability [21 CFR 606.100(b)] in that collection from a donor occurred more frequently than twice in a 7-day period.

Neither this letter nor the list of inspectional observations form (FDA-483) is meant to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility as management to assure that your establishment is in compliance with all requirements of the Federal regulations.


You should notify this office in writing within 15 working days of receipt of this letter, of any steps you have taken or will take to correct the noted violations and to

Page Two

Richard Devoll
August 14, 2000

prevent their recurrence. If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Failure to promptly correct these deviations may result in regulatory action without further notice. Such actions include license suspension, revocation, and seizure. Your reply should be directed to Compliance Officer Judy E. Heisick at the address indicated on the letterhead.

Sincerely,



James A. Rahto
Director
Minneapolis District

JEH/ccl

xc: Melva J. Lorenz
Center Manager
Seramed, Inc.
2111 West North Avenue
Milwaukee, WI 53205